pharmacy checklist
503A vs 503B Tirzepatide Pharmacy Checklist: What Patients Should Verify in 2026
A practical pharmacy-verification checklist for compounded tirzepatide patients comparing 503A pharmacies, 503B outsourcing facilities, and telehealth providers.
Last updated 2026-06-13Source checked against FDA / public pricing pagesCompounded medications are not FDA-approved
Direct answer: A 503A pharmacy generally compounds for individual patient prescriptions. A 503B outsourcing facility can compound under a different federal framework and is subject to different requirements. For tirzepatide, patients should verify the actual dispensing pharmacy, state license, whether the prescription is patient-specific, and whether the medication is legally available at the time of fill.
The practical difference
Patients do not need to memorize the statute. They need to know what to ask before paying. A 503A pharmacy is commonly the patient-specific prescription route. A 503B outsourcing facility has different registration and quality requirements, but that does not automatically mean any GLP-1 product can be compounded at any time.
Verification checklist
- Ask for the pharmacy name before payment when possible.
- Confirm the pharmacy is licensed in the state where the patient lives.
- Ask whether the prescription is reviewed by a licensed provider for the specific patient.
- Ask whether the medication is compounded and not FDA-approved.
- Ask what quality documentation is available to the prescriber or pharmacy.
- Avoid sellers that do not require a prescription.
Red flags
| Red flag | Why it matters |
|---|
| No prescription required | Tirzepatide should not be sold as a no-prescription consumer product. |
| "Generic Zepbound" language | FDA has warned against claims that compounded GLP-1 products are generic or the same as approved drugs. |
| No pharmacy disclosure at all | Patients cannot verify licensing or quality standards. |
| Unclear dosing instructions | GLP-1 dosing errors can cause serious side effects. |
How this improves SEO/AEO
Pages that give patients a practical verification checklist are more useful than pages that only list prices. This creates original editorial value and gives answer engines clear, safe steps to summarize.
Sources and source standard
Medical and regulatory note: This site is an editorial reference, not a prescribing platform. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Patients should use this content to ask better questions of a licensed provider and should verify current pricing, eligibility, pharmacy, and state availability directly before ordering.
503A pharmacies vs 503B outsourcing facilities
Two legal compounding pathways matter for patients. A 503A pharmacy is licensed by a state board and prepares patient-specific prescriptions; sterile injectables should be compounded under USP General Chapter <797> standards. A 503B outsourcing facility is registered with the FDA, follows current good manufacturing practice (cGMP), can prepare larger batches, and is subject to FDA inspection. Neither pathway makes a compounded product “FDA-approved.” What matters for a patient is that the dispensing pathway is disclosed, the active ingredient is tirzepatide base from an FDA-registered supplier, and each prescription is patient-specific and clinically justified.
503A vs 503B at a glance
| Dimension | 503A pharmacy | 503B outsourcing facility |
|---|
| Primary oversight | State board of pharmacy | FDA registration and inspection |
| Standard | USP <797> sterile compounding | Current good manufacturing practice (cGMP) |
| Prescriptions | Patient-specific | Can prepare larger batches for providers |
| Typical use | Individualized compounded prescriptions | Office-use and larger-scale supply |
Neither pathway makes a compounded product FDA-approved, and both can be legitimate. What patients should look for is disclosure: a provider that will tell you which pathway fills your prescription and the name of the pharmacy is being transparent in exactly the way that matters.
Your verification checklist
- Confirm a licensed clinician evaluates you and writes a patient-specific prescription.
- Ask whether a 503A pharmacy, a 503B facility, or both will fill it — and get the name.
- Confirm the active ingredient is tirzepatide base from an FDA-registered supplier.
- Ask how sterility and quality are assured (USP <797> for 503A; cGMP for 503B).
- Confirm refrigerated shipping and clear storage instructions.
- Confirm the pharmacy can legally ship to your state.
What the shortage status change means
During the tirzepatide shortage, compounding had more latitude. After the FDA considered the shortage resolved and removed tirzepatide from its drug-shortage list, the rules tightened, and the clearest remaining path runs through patient-specific 503A compounding and FDA-registered 503B facilities under the conditions in section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Because this area continues to evolve, verify a provider’s current pharmacy practices rather than relying on older shortage-era marketing.
Important: Compounded tirzepatide is not FDA-approved and is not the same medicine as Mounjaro or Zepbound, which are the only FDA-approved tirzepatide products (manufactured by Eli Lilly and Company). This page is educational and is not medical advice. Telehealth medications require evaluation and, when appropriate, a prescription from a licensed clinician. Always confirm current pricing and pharmacy details directly with a provider before purchasing.
Why pharmacy disclosure is the single most useful signal
Of everything a patient can check, the willingness of a provider to name its pharmacy and pathway is the most telling. A provider that says, plainly, “your prescription is filled by a named 503A pharmacy licensed in your state” or “a named FDA-registered 503B outsourcing facility” is giving you the one fact you can independently look up. A provider that deflects, gives a vague answer, or treats the question as unreasonable is telling you something just as clearly. Sterility and quality of an injectable depend on the facility that prepares it, so the pharmacy is not a back-office detail — it is the product. Treat disclosure as a baseline requirement, not a bonus, and let any provider that fails this test fall off your list before you ever compare prices.
Reminder: this page is educational, not medical advice, and compounded tirzepatide is not FDA-approved or identical to Mounjaro or Zepbound. Confirm current pricing, state availability, and pharmacy details directly with a licensed provider before making any decision.